---
title: "Gilead Sciences (GILD) news: class action and offering"
url: "https://aibio.space/companies/gilead-sciences/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "GILD class action, offering and settlement news. Gilead Sciences news for investors: Gilead Sciences makes HIV, liver disease and cancer drugs, led by the…"
---

Desk view · Opinion · Updated Oct 22, 2026

## Gilead bought its next act. Now it has to sell it

Gilead has a growing HIV base and a run of 2026 approvals, but it spent most of its cash on deals that still have to prove themselves. The anito-cel decision in December and Yeztugo persistence are the two numbers that will say whether the bet pays.

Read the full desk view

aibio.space Investor Rank · Opinion

**8** /10 Positive view

A growing HIV base and several 2026 approvals, but cash fell to $3.18 billion after deals that still need to prove themselves, and HIV dominates sales.

- **Technology**: 2/2

- **Odds**: 2/2

- **Balance sheet**: 1/2

- **Risk**: 1/2

- **Momentum**: 2/2

Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank).

- **Technology**: **Long-acting HIV leader.** Lenacapavir now underpins a twice-yearly PrEP shot, a daily tablet and a weekly oral regimen that matched Biktarvy in phase 3.

- **Odds**: **Mostly late stage.** Anito-cel is filed with a December 23 PDUFA date, and filed drugs historically reach approval about 90% of the time.

- **Balance sheet**: **Profitable but stretched.** Cash fell to $3.18 billion at June 30 from $10.6 billion after about $11 billion in deals, with new debt taken on.

- **Main risk**: **HIV concentration.** About three quarters of product sales come from HIV, and new products partly move revenue from Biktarvy.

- **Watch next**: **Q3 then anito-cel.** Results land October 29 and the anito-cel FDA decision is due December 23.

## Top news on Gilead

1. 2026-08-06 Legal [Gilead HIV antitrust appeal awaits ruling after October 2025 argument; Aetna trial set for 2027](https://aibio.space/news/gilead-hiv-antitrust-appeal-awaits-ruling-after-october-2025-argument/) Gilead, Bristol-Myers Squibb, Johnson & Johnson and Teva are defendants in consolidated federal suits over HIV drugs. Gilead paid $525 million in 2023 to settle with the direct purchaser class and retailer opt-out plaintiffs.
2. 2026-08-06 Legal [Gilead cites August 2026 ruling in HIV drug injury suits with about 23,000 active plaintiffs](https://aibio.space/news/gilead-cites-august-2026-ruling-hiv-drug-injury-suits-about-23-000/) The 10-Q names Gilead as defendant, with no co-defendants listed, in a putative class action and product liability suits over Viread, Truvada, Atripla, Complera and Stribild. A federal bellwether trial is set for March 2027.
3. 2026-08-05 Financings [Arcus ends last TIGIT phase 3 as Gilead gives up its three board seats](https://aibio.space/news/arcus-ends-last-tigit-phase-3-gilead-gives-up-three-board-seats/) Arcus and AstraZeneca will stop PACIFIC-8 in stage III lung cancer. Second-quarter cash was $775 million, with runway guided to at least the second half of 2028.
4. 2026-05-14 Debt Financing [Gilead sells senior notes due 2028 through 2034 in public offering](https://aibio.space/news/gilead-sells-senior-notes-due-2028-through-2034-public-offering/) Gilead sold four series of senior notes due 2028 through 2034 in a public offering, with coupons from 4.250% to 4.900%. Barclays, BofA Securities and Citigroup Global Markets are the representatives of the underwriters.

## Dates

**October 29, 2026**
Third-quarter 2026 results and guidance [Source](https://www.gilead.com/news/news-details/2026/gilead-sciences-to-release-third-quarter-2026-financial-results-on-thursday-october-29-2026)

**December 23, 2026**
FDA decision date for anito-cel in fourth-line-plus multiple myeloma [Source](https://s29.q4cdn.com/585078350/files/doc_financials/2026/q2/GILD-Q226-Prepared-Remarks-4-August-2026.pdf)

**Later in 2026**
Trodelvy ASCENT-GYN phase 3 update in endometrial cancer [Source](https://s29.q4cdn.com/585078350/files/doc_financials/2026/q2/GILD-Q226-Prepared-Remarks-4-August-2026.pdf)

**February 2, 2027**
FDA decision on once-weekly oral lenacapavir for PrEP [Source](https://www.sec.gov/Archives/edgar/data/0000882095/000088209526000028/exhibit991earningspressrel.htm)

## The money

$3.18 billion in cash, cash equivalents and marketable debt securities at June 30, 2026 (Q2), down from $10.6 billion at December 31, 2025, after acquisitions. No runway guidance given; operating margin excluding acquired IPR&D was about 49% in Q2. [Source](https://www.sec.gov/Archives/edgar/data/0000882095/000088209526000028/exhibit991earningspressrel.htm)

Q2 2026 total revenue $7.80 billion, up 10%; product sales $7.63 billion. 2026 product sales guidance $30.1 billion to $30.4 billion. [Source](https://www.sec.gov/Archives/edgar/data/0000882095/000088209526000028/exhibit991earningspressrel.htm)

## Risks on the record

- HIV drugs made $5.69 billion of $7.63 billion in Q2 product sales, so the company depends on one franchise, and new lenacapavir products partly compete with Biktarvy. [Source](https://www.sec.gov/Archives/edgar/data/0000882095/000088209526000028/exhibit991earningspressrel.htm)
- Cell therapy sales fell 14% to $417 million in Q2 on competition. [Source](https://www.sec.gov/Archives/edgar/data/0000882095/000088209526000028/exhibit991earningspressrel.htm)
- The phase 3 EVOKE-03 trial of Trodelvy plus Keytruda in first-line PD-L1-high lung cancer was stopped for futility in June 2026. [Source](https://www.onclive.com/view/keynote-d46-trial-is-discontinued-with-sacituzumab-govitecan-plus-pembrolizumab-in-pd-l1-high-nsclc)

## Questions investors ask

### What is aibio.space's Investor Rank for Gilead Sciences?

8 out of 10, our positive view. A growing HIV base and several 2026 approvals, but cash fell to $3.18 billion after deals that still need to prove themselves, and HIV dominates sales. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank)

### When does Gilead report Q3 2026 earnings?

Gilead will release third-quarter 2026 results after the market closes on Thursday, October 29, 2026, with a webcast at 4:30 p.m. Eastern. [Source](https://www.gilead.com/news/news-details/2026/gilead-sciences-to-release-third-quarter-2026-financial-results-on-thursday-october-29-2026)

### How much did Yeztugo sell in Q2 2026?

Yeztugo sales were $232 million in the second quarter of 2026, up 40% from the first quarter. Gilead expects about $1 billion in 2026 Yeztugo sales. [Source](https://s29.q4cdn.com/585078350/files/doc_financials/2026/q2/GILD-Q226-Prepared-Remarks-4-August-2026.pdf)

### When is the FDA decision on anito-cel?

The FDA's target action date for anito-cel in fourth-line and later relapsed or refractory multiple myeloma is December 23, 2026. Gilead took full ownership of the therapy when it completed the Arcellx acquisition. [Source](https://s29.q4cdn.com/585078350/files/doc_financials/2026/q2/GILD-Q226-Prepared-Remarks-4-August-2026.pdf)

### What is Bixlenvo?

Bixlenvo is a once-daily tablet of bictegravir 75 mg and lenacapavir 50 mg, approved by the FDA in August 2026 for adults with suppressed HIV who have no known resistance to either drug. Gilead calls it the first single-tablet option for suppressed patients on complex regimens. [Source](https://gilead.com/news/news-details/2026/u-s--fda-approves-gileads-bixlenvo-a-new-once-daily-single-tablet-option-for-virologically-suppressed-adults-with-hiv-including-those-on-complex-regimens)

### Why did Gilead report a loss in Q2 2026?

Gilead booked a GAAP loss of $8.45 per share because of a $9.08 per-share charge for acquired in-process R&D from the Arcellx, Tubulis and Ouro Medicines deals. Revenue still grew 10% to $7.80 billion. [Source](https://www.sec.gov/Archives/edgar/data/0000882095/000088209526000028/exhibit991earningspressrel.htm)

### What is the latest Gilead Sciences (GILD) stock news?

Our latest story on Gilead Sciences, dated Aug 6, 2026: "Gilead HIV antitrust appeal awaits ruling after October 2025 argument; Aetna trial set for 2027". Gilead, Bristol-Myers Squibb, Johnson & Johnson and Teva are defendants in consolidated federal suits over HIV drugs. Gilead paid $525 million in 2023 to settle with the direct purchaser class and retailer opt-out plaintiffs. [Source](https://aibio.space/news/gilead-hiv-antitrust-appeal-awaits-ruling-after-october-2025-argument/)

### Does Gilead Sciences have debt, a term loan or convertible notes?

Our latest debt story, dated May 14, 2026: "Gilead sells senior notes due 2028 through 2034 in public offering". Gilead sold four series of senior notes due 2028 through 2034 in a public offering, with coupons from 4.250% to 4.900%. Barclays, BofA Securities and Citigroup Global Markets are the representatives of the underwriters. [Source](https://aibio.space/news/gilead-sells-senior-notes-due-2028-through-2034-public-offering/)

### Is Gilead Sciences facing a lawsuit?

Our latest legal story, dated Aug 6, 2026: "Gilead HIV antitrust appeal awaits ruling after October 2025 argument; Aetna trial set for 2027". Gilead, Bristol-Myers Squibb, Johnson & Johnson and Teva are defendants in consolidated federal suits over HIV drugs. Gilead paid $525 million in 2023 to settle with the direct purchaser class and retailer opt-out plaintiffs. Claims in lawsuits are allegations until a court rules. [Source](https://aibio.space/news/gilead-hiv-antitrust-appeal-awaits-ruling-after-october-2025-argument/)

### What is Gilead Sciences's market cap?

We do not publish live share prices. In its annual report, Gilead Sciences, Inc. put the market value of shares held by non-affiliates (public float) at $103.20 billion as of Jun 30, 2025. Source

### Is Gilead Sciences a smaller reporting company?

SEC records list Gilead Sciences, Inc.'s filer category as: Large accelerated filer. Source

### Where is Gilead Sciences headquartered?

SEC records list its business address as 333 LAKESIDE DR, FOSTER CITY, CA, 94404. Source

### When does Gilead Sciences's fiscal year end?

Gilead Sciences, Inc.'s fiscal year ends on December 31, per SEC records. Source

### What did Gilead Sciences last file with the SEC?

Its most recent filing in our record is a 10-Q filed 2026-08-06. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/gild-20260630.htm)

### What was Gilead Sciences called before?

SEC records list these former names: GILEAD SCIENCES INC. Source

## Legal and investor matters

Checked against Gilead Sciences filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026.

Gilead's 10-Q filed 2026-08-06 (Note 10, Legal Proceedings) says Gilead is a party to various legal actions and describes certain significant matters, including antitrust, product liability, qui tam and patent matters. [Source](https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/gild-20260630.htm)

1. 2026-08-06 Litigation California Supreme Court rules for Gilead in HIV drug injury cases Gilead says in its 10-Q filed 2026-08-06 that in August 2026 the California Supreme Court ruled in its favor in the state product liability cases over Viread, Truvada, Atripla, Complera and Stribild. The court concluded the plaintiffs' negligence claim could not proceed as a matter of law and directed summary judgment for Gilead on all causes of action. The filing counts about 23,000 active plaintiffs across state and federal courts in California and Missouri. California Supreme Court [Gilead Form 10-Q (2026-08-06)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/gild-20260630.htm)
2. 2026-05-20 Financing Gilead issues four series of senior notes in a public offering On 2026-05-20 Gilead and its trustee signed a supplemental indenture for four series of senior notes sold under its shelf registration statement. The series are $500 million of 4.250% notes due 2028, $1.0 billion of 4.400% notes due 2029, $1.0 billion of 4.600% notes due 2031 and $500 million of 4.900% notes due 2034, for $3.0 billion in total principal. [Gilead Form 8-K](https://www.sec.gov/Archives/edgar/data/882095/000110465926064518/tm2615045d1_8k.htm)
3. 2026-05-07 Litigation Gilead sues Cipla over Descovy 505(b)(2) application in Delaware Gilead disclosed in its 10-Q filed 2026-05-07 that in January 2026 Cipla told it that it had filed a 505(b)(2) application for emtricitabine/tenofovir alafenamide tablets referencing Descovy and challenging two Orange Book patents. Gilead sued Cipla in the District of Delaware in February 2026. The filing gives no trial date. U.S. District Court for the District of Delaware · Status: pending [Gilead Form 10-Q (2026-05-07)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000024/gild-20260331.htm)
4. 2026-04-28 Other Gilead completes acquisition of Arcellx Gilead said on 2026-04-28 that it completed its acquisition of Arcellx, Inc. under the merger agreement signed 2026-02-22. The tender offer began 2026-03-06 at $115.00 per share in cash plus one contingent value right paying $5.00, subject to cumulative worldwide sales of Arcellx's product. Gilead's 10-Q for the quarter ended 2026-06-30 says its effective tax rate differed from the statutory rate primarily because of non-deductible acquired IPR&D expense from the Arcellx, Tubulis and Ouro Medicines acquisitions. [Gilead Form 8-K](https://www.sec.gov/Archives/edgar/data/882095/000110465926049874/tm2612748d1_8k.htm)
5. 2026-02-24 Litigation Missouri court denies class certification in HIV drug product liability case In its 10-K filed 2026-02-24, Gilead said the district court in the Missouri putative class action over Viread, Truvada, Atripla, Complera and Stribild denied the plaintiffs' motion for class certification in January 2026. The plaintiffs petitioned the Eighth Circuit for review. The 10-Q filed 2026-05-07 says the Eighth Circuit denied that request for interlocutory review. U.S. District Court, Missouri; Eighth Circuit · Status: pending [Gilead Form 10-K (2026-02-24)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/gild-20251231.htm)
6. 2026-02-23 Other Gilead agrees to acquire Arcellx in a cash tender offer Gilead disclosed on 2026-02-23 that it signed a merger agreement with Arcellx, Inc. on 2026-02-22. Under it, a Gilead subsidiary would launch a tender offer for all Arcellx shares at $115.00 per share in cash, plus one contingent value right paying $5.00 if a cumulative sales milestone is met. [Gilead Form 8-K](https://www.sec.gov/Archives/edgar/data/882095/000110465926018314/tm267044d1_8k.htm)
7. 2025-11-07 Litigation Appeal argued in Gilead HIV antitrust class actions; Aetna trial set for 2027 The 10-Q filed 2025-11-07 says oral argument on the plaintiffs' appeal of the 2023 jury verdict for Gilead on the Truvada and Atripla claims took place in October 2025 in the consolidated Northern District of California antitrust cases. Phase II is stayed pending that appeal. Aetna's separate California state suit is set for trial in January 2027. U.S. District Court for the Northern District of California · Status: appealed [Gilead Form 10-Q (2025-11-07)](https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/gild-20250930.htm)
8. 2025-11-07 Litigation Federal court dismisses HCV False Claims Act case against Gilead Gilead disclosed in its 10-Q filed 2025-11-07 that in September 2025 the Eastern District of Pennsylvania granted its summary judgment motion and dismissed a qui tam suit alleging its hepatitis C sales and marketing and charity donations violated the False Claims Act. The relator has appealed. A separate Texas qui tam suit by Health Choice Advocates, joined by the Texas attorney general, is set for trial in December 2026. U.S. District Court for the Eastern District of Pennsylvania · Status: appealed [Gilead Form 10-Q (2025-11-07)](https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/gild-20250930.htm)
9. 2025-10-06 Litigation Gilead settles Biktarvy patent suits with Lupin, Cipla and Laurus Gilead announced on 2025-10-06 that it settled patent litigation with generic makers Lupin, Cipla and Laurus Labs over their applications to sell generic Biktarvy. Under the agreements, no generic entry is expected in the United States before 2036-04-01, subject to standard acceleration provisions. Status: settled [Gilead Form 8-K](https://www.sec.gov/Archives/edgar/data/882095/000088209525000041/gild-20251006.htm)
10. 2024-11-20 Financing Gilead issues four series of senior notes totaling $3.5 billion On 2024-11-20 Gilead signed a supplemental indenture for four series of senior notes sold under its shelf registration: $750 million of 4.80% notes due 2029, $1.0 billion of 5.10% notes due 2035, $1.0 billion of 5.50% notes due 2054 and $750 million of 5.60% notes due 2064. Gilead said proceeds are for general corporate purposes, which may include repaying debt. [Gilead Form 8-K](https://www.sec.gov/Archives/edgar/data/882095/000110465924121025/tm2426602d4_8k.htm)

## Pipeline

| Program | Indication | Stage |
|---|---|---|
| Anito-cel (anitocabtagene autoleucel) | Relapsed or refractory multiple myeloma, fourth line and later | BLA filed, PDUFA December 23, 2026 [Source](https://s29.q4cdn.com/585078350/files/doc_financials/2026/q2/GILD-Q226-Prepared-Remarks-4-August-2026.pdf) |
| Lenacapavir once-weekly oral | HIV pre-exposure prophylaxis | sNDA accepted, decision by February 2, 2027 [Source](https://www.sec.gov/Archives/edgar/data/0000882095/000088209526000028/exhibit991earningspressrel.htm) |
| Islatravir/lenacapavir weekly oral | HIV treatment, virologically suppressed adults | Phase 3 positive (ISLEND-1, ISLEND-2), filing planned [Source](https://www.gilead.com/news/news-details/2026/gilead-and-merck-announce-positive-topline-results-from-two-phase-3-studies-evaluating-islatravirlenacapavir-an-oral-once-weekly-hiv-treatment) |
| Trodelvy (sacituzumab govitecan) | Endometrial cancer (ASCENT-GYN) | Phase 3, update expected later in 2026 [Source](https://s29.q4cdn.com/585078350/files/doc_financials/2026/q2/GILD-Q226-Prepared-Remarks-4-August-2026.pdf) |
| Livdelzi (seladelpar) | Primary biliary cholangitis, ALP 1.0 to 1.67x ULN | Phase 3 IDEAL positive, expansion as early as 2027 [Source](https://www.sec.gov/Archives/edgar/data/0000882095/000088209526000028/exhibit991earningspressrel.htm) |
| GS-8824 (NaPi2b ADC) | Platinum-resistant ovarian cancer | Early clinical, registrational start as early as 2027 [Source](https://s29.q4cdn.com/585078350/files/doc_financials/2026/q2/GILD-Q226-Prepared-Remarks-4-August-2026.pdf) |

Opinion · Devil's advocate

## Fact-check-o-meter

Consistent

Gilead's releases mostly match its 10-Q, with thin topline data and an impairment the release does not tie to the lung study

Gilead's second-quarter release gave GAAP and non-GAAP figures side by side and disclosed the EVOKE-03 lung cancer stop, so the big numbers line up with the 10-Q. The softer spots are science ones: the weekly HIV pill was announced with no efficacy figures, and the new first-line Trodelvy label rests on progression-free survival while overall survival is still being followed.

1. Press release vs filing · weight low Upbeat quarter quote sits beside a $1.75 billion write-off **The company said:** "We also made significant clinical progress with three FDA approvals and three positive Phase 3 updates." [source](https://www.sec.gov/Archives/edgar/data/882095/000088209526000028/exhibit991earningspressrel.htm) **The record says:** The 10-Q ties the charge directly to the failed lung cancer study: "In consideration of this decision, and in connection with the preparation of the financial statements for the second quarter of 2026, we determined that no future cash flows were expected to be generated in relation to the NSCLC IPR&D intangible asset, and therefore, no value was attributed to the asset. As a result, we recognized an impairment charge of the remaining balance of $1.75 billion." The release lists the EVOKE-03 discontinuation in its pipeline section but describes the charge in its narrative text only as "an IPR&D impairment related to assets previously acquired from Immunomedics, Inc." [source](https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/gild-20260630.htm) **Our view:** Nothing is hidden here, since both facts are in the release. But a reader has to connect them alone, and the 10-Q is the place that says the first-line lung cancer value of the Immunomedics deal is now written to zero.
2. Press release vs filing · weight low "Very strong" quarter was a $10.5 billion GAAP loss **The company said:** "Gilead delivered a very strong second quarter, with 10% year-over-year revenue growth in our base business driven by our HIV portfolio, Trodelvy and Livdelzi." [source](https://www.sec.gov/Archives/edgar/data/882095/000088209526000028/exhibit991earningspressrel.htm) **The record says:** The 10-Q income statement shows a net loss of $10,496 million for the three months ended June 30, 2026, against net income of $1,960 million a year earlier, driven by acquired IPR&D from the Arcellx, Tubulis and Ouro Medicines deals. The 10-Q also notes Biktarvy growth was "primarily due to higher average realized price, favorable inventory dynamics and higher demand." [source](https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/gild-20260630.htm) **Our view:** The release does print the $(8.45) GAAP loss per share in its sub-headline, so this is framing, not omission. The operating business did grow; the loss is deal accounting. The inventory and price contribution to Biktarvy is worth tracking because the 10-Q warns second-half wholesaler buying is often followed by draw-downs.
3. Science · weight medium Weekly HIV pill topline came with no numbers **The company said:** "In the double-blind ISLEND-1 trial, the once-weekly, single-tablet regimen of ISL/LEN was found to be statistically non-inferior to BIKTARVY. In the open-label ISLEND-2 trial, ISL/LEN was found to be statistically non-inferior to standard of care daily oral antiretroviral therapy regimens." [source](https://www.gilead.com/news/news-details/2026/gilead-and-merck-announce-positive-topline-results-from-two-phase-3-studies-evaluating-islatravirlenacapavir-an-oral-once-weekly-hiv-treatment) **The record says:** ClinicalTrials.gov lists ISLEND-2 (NCT06630299) with no masking (open label) and an estimated enrollment of 600; ISLEND-1 (NCT06630286) enrolled 609 and is double-blind. Both records list change from baseline in CD4 T-cell count at Week 48 as a secondary outcome. The June 8 release gives no virologic failure rates, no CD4 data and no discontinuation rates, only that safety was "generally comparable" and that no new safety concerns were identified. [source](https://clinicaltrials.gov/study/NCT06630299) **Our view:** Non-inferiority in suppressed switch patients is the expected bar, and one of the two trials is blinded, which helps. Until the snapshot rates and CD4 changes are presented at a congress, investors are taking the safety summary on the companies' word.
4. Science · weight medium First-line Trodelvy approval rests on PFS, survival still open **The company said:** "The FDA approval is based on highly statistically significant and clinically meaningful progression-free survival (PFS) data from the Phase 3 ASCENT-03 and ASCENT-04/KEYNOTE-D19 trials" [source](https://www.gilead.com/news/news-details/2026/u-s--fda-approves-trodelvy-for-first-line-treatment-of-metastatic-triple-negative-breast-cancer) **The record says:** ClinicalTrials.gov lists ASCENT-03 (NCT05382299) as open-label (no masking), with PFS by blinded central review as the primary outcome, "Overall Survival (OS)" as a secondary outcome, and an estimated primary completion of July 2028. The release cites overall survival benefits only for second-line TNBC and pre-treated HR+/HER2- disease. Its safety section reports fatal adverse reactions in 2.5% of ASCENT-03 patients and 3.2% of ASCENT-04 patients. [source](https://clinicaltrials.gov/study/NCT05382299) **Our view:** PFS read by blinded central review is a standard basis for approval in this setting, and the release is clear that PFS is what was shown. The first-line survival result is the open question for how durable this label and the NCCN preference will be.
5. Legal and disclosure record · weight low Antitrust, product liability and qui tam cases, no securities suit **The record says:** Note 10 of the 10-Q discloses consolidated HIV antitrust class actions in the U.S. District Court for the Northern District of California (Phase I verdict for Gilead, appeal argued October 2025, Phase II stayed); an Aetna opt-out suit in San Mateo County Superior Court with trial "scheduled for January 2027"; product liability suits over tenofovir drugs that "involve approximately 23,000 active plaintiffs," with a federal bellwether trial set for March 2027; and a Texas Medicare Fraud Prevention Act qui tam suit in which "the Texas Attorney General has intervened as a plaintiff. Trial has been scheduled for December 2026." It also discloses a February 2026 patent suit against Cipla in the District of Delaware over Descovy. No securities class action or SEC enforcement matter is disclosed. [source](https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/gild-20260630.htm) **Our view:** These are long-running matters that Gilead discloses in detail, and the 10-Q says it had no material accruals for them at June 30. The dated items to watch are the Texas trial in December 2026 and the Aetna and federal bellwether trials in early 2027.

Documents we compared

- [Gilead Q2 2026 earnings press release (Form 8-K Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000028/exhibit991earningspressrel.htm) 2026-08-04
- [Gilead Form 10-Q for the quarter ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/gild-20260630.htm) 2026-08-06
- [Gilead and Merck ISLEND-1 and ISLEND-2 topline release](https://www.gilead.com/news/news-details/2026/gilead-and-merck-announce-positive-topline-results-from-two-phase-3-studies-evaluating-islatravirlenacapavir-an-oral-once-weekly-hiv-treatment) 2026-06-08
- [FDA approves Trodelvy for first-line mTNBC, Gilead release](https://www.gilead.com/news/news-details/2026/u-s--fda-approves-trodelvy-for-first-line-treatment-of-metastatic-triple-negative-breast-cancer) 2026-06-24
- [ClinicalTrials.gov NCT06630286 (ISLEND-1)](https://clinicaltrials.gov/study/NCT06630286) 2026-10-23
- [ClinicalTrials.gov NCT06630299 (ISLEND-2)](https://clinicaltrials.gov/study/NCT06630299) 2026-10-23
- [ClinicalTrials.gov NCT05382299 (ASCENT-03)](https://clinicaltrials.gov/study/NCT05382299) 2026-10-23

This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply).

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:GILD on TradingView](https://www.tradingview.com/symbols/NASDAQ-GILD/).

## SEC filings and registration

- **SEC name**: Gilead Sciences, Inc.

- **CIK**: 882095

- **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836)

- **US tickers**: GILD (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Large accelerated filer

- **Business address**: 333 LAKESIDE DR, FOSTER CITY, CA, 94404

- **Phone**: 6505743000

- **Shares outstanding**: 1,239,955,155 as of 2026-07-31 (10-Q filed 2026-08-06)

- **Former names**: GILEAD SCIENCES INC

### Recent filings (8-K and 6-K are the company's own announcements)

- [10-Q](https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/gild-20260630.htm) filed 2026-08-06
- [8-K](https://www.sec.gov/Archives/edgar/data/882095/000088209526000028/gild-20260804.htm) filed 2026-08-04
- [8-K](https://www.sec.gov/Archives/edgar/data/882095/000110465926064518/tm2615045d1_8k.htm) filed 2026-05-20
- [424B5](https://www.sec.gov/Archives/edgar/data/882095/000110465926063199/tm2531124-2_424b5.htm) filed 2026-05-18
- [424B5](https://www.sec.gov/Archives/edgar/data/882095/000110465926060745/tm2531124-1_424b5.htm) filed 2026-05-14
- [10-Q](https://www.sec.gov/Archives/edgar/data/882095/000088209526000024/gild-20260331.htm) filed 2026-05-07
- [8-K](https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/gild-20260507.htm) filed 2026-05-07
- [8-K](https://www.sec.gov/Archives/edgar/data/882095/000088209526000008/gild-20260430.htm) filed 2026-05-04

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/gilead-sciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Gilead Sciences (GILD) news: class action and offering", 2026-10-31, https://aibio.space/companies/gilead-sciences/